a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis ...

ABSTRACT: CD200:CD200R interactions regulate immune responses. Since CD200Rs show extensive homology in their extracellular region, generating anti-CD200R specific antibodies is a challenge. We report ...

These pathways could suppress CD200R expression, ultimately leading to reduced serum concentrations of sCD200R. The study included 70 patients with AAV, with a median age of 63.5 years.

The direct immunologic role of CD200 and CD200R in AAV pathogenesis is still unclear. However, the researchers suggested that increased inflammation during active disease may increase CD200 expression ...

a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis ...

ARQ-234 - a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 Receptor (CD200R), being developed as a potential biologic treatment in atopic dermatitis.

The researchers identified a unique subset of HSCs that express high levels of NO (termed "NO hi HSCs") and discovered these cells also contain high levels of the immunomodulatory receptor CD200R ...

Controlling pro-inflammatory responses helps reduce brain ischemic injury and has translational significance. The interaction between CD200R, an inhibitory receptor on immune cells, and the CD200 ...

They were highly quiescent, expressed immunomodulatory molecules like CD200R, and exhibited robust reconstitution over time, particularly after serial transplantation. NOhi HSCs were predominantly ...